K.M. Kerr

3.0k total citations · 1 hit paper
34 papers, 1.5k citations indexed

About

K.M. Kerr is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, K.M. Kerr has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in K.M. Kerr's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Balance, Gait, and Falls Prevention (5 papers). K.M. Kerr is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Balance, Gait, and Falls Prevention (5 papers). K.M. Kerr collaborates with scholars based in United Kingdom, United States and Spain. K.M. Kerr's co-authors include Martin Reck, Enriqueta Felip, Solange Peters, Alex A. Adjei, Cesare Gridelli, Rab Mollan, D Lamb, Andrew Kerr, Brian Durward and Esmaeil Nikfekr and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and British Journal of Cancer.

In The Last Decade

K.M. Kerr

33 papers receiving 1.5k citations

Hit Papers

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clini... 2012 2026 2016 2021 2012 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.M. Kerr United Kingdom 16 857 568 276 266 235 34 1.5k
Keisuke Kubota Japan 18 349 0.4× 145 0.3× 66 0.2× 52 0.2× 25 0.1× 94 911
Hye‐Rim Park South Korea 15 179 0.2× 162 0.3× 124 0.4× 46 0.2× 57 0.2× 51 625
George Chen United States 10 59 0.1× 167 0.3× 229 0.8× 74 0.3× 19 0.1× 29 715
Yimin Zhang China 17 207 0.2× 402 0.7× 272 1.0× 7 0.0× 232 1.0× 100 1.2k
Naveed Akhtar Qatar 23 1.0k 1.2× 168 0.3× 192 0.7× 5 0.0× 88 0.4× 142 2.3k
Helle Westergren Hendel Denmark 23 331 0.4× 909 1.6× 306 1.1× 3 0.0× 107 0.5× 70 2.2k
Raffaella Capasso Italy 14 174 0.2× 93 0.2× 74 0.3× 6 0.0× 43 0.2× 58 734
Ryota Ishii Japan 12 109 0.1× 117 0.2× 108 0.4× 5 0.0× 56 0.2× 72 596
Petra Georg Austria 25 531 0.6× 218 0.4× 87 0.3× 7 0.0× 86 0.4× 56 3.3k
Bo He China 17 158 0.2× 270 0.5× 297 1.1× 2 0.0× 214 0.9× 61 1.2k

Countries citing papers authored by K.M. Kerr

Since Specialization
Citations

This map shows the geographic impact of K.M. Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.M. Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.M. Kerr more than expected).

Fields of papers citing papers by K.M. Kerr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.M. Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.M. Kerr. The network helps show where K.M. Kerr may publish in the future.

Co-authorship network of co-authors of K.M. Kerr

This figure shows the co-authorship network connecting the top 25 collaborators of K.M. Kerr. A scholar is included among the top collaborators of K.M. Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.M. Kerr. K.M. Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fernandes, Timothy M., Demosthenes G. Papamatheakis, David Poch, et al.. (2020). Risk Factors and Outcomes for Patients Requiring Repeat Thromboendarterectomy. A6065–A6065. 1 indexed citations
2.
Felip, Eudald, Julie R. Brahmer, Stephen Broderick, et al.. (2018). P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC. Journal of Thoracic Oncology. 13(10). S831–S832. 19 indexed citations
3.
Rittmeyer, Achim, Shirish M. Gadgeel, Marcin Kowanetz, et al.. (2018). Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study. Pneumologie. 72(S 01). S50–S51. 3 indexed citations
4.
Baas, Paul, et al.. (2015). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro). Annals of Oncology. 26. 3 indexed citations
5.
Kerr, K.M., et al.. (2015). Survival from malignant mesothelioma: where are we now?. The Journal of the Royal College of Physicians of Edinburgh. 45(2). 123–126. 15 indexed citations
6.
Patton, Simon, Nicola Normanno, Fiona Blackhall, et al.. (2014). Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer. 111(2). 413–420. 33 indexed citations
7.
Pretorius, Victor, K.M. Kerr, Peter F. Fedullo, et al.. (2014). Complete Pulmonary Artery Occlusion from Chronic Thromboembolic Disease: Outcomes Following Pulmonary Thromboendarterectomy Surgery. The Journal of Heart and Lung Transplantation. 33(4). S54–S54. 2 indexed citations
8.
Peters, Solange, Alex A. Adjei, Cesare Gridelli, et al.. (2012). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23. vii56–vii64. 791 indexed citations breakdown →
9.
Kerr, Andrew, Danny Rafferty, K.M. Kerr, & Brian Durward. (2006). Timing phases of the sit-to-walk movement: Validity of a clinical test. Gait & Posture. 26(1). 11–16. 45 indexed citations
10.
Kerr, Andrew, Brian Durward, & K.M. Kerr. (2004). Defining phases for the sit-to-walk movement. Clinical Biomechanics. 19(4). 385–390. 70 indexed citations
11.
Nikfekr, Esmaeil, K.M. Kerr, S. Attfield, & E. Diane Playford. (2002). Trunk movement in Parkinson's disease during rising from seated position. Movement Disorders. 17(2). 274–282. 47 indexed citations
12.
Kerr, Andrew & K.M. Kerr. (2001). Differences in the Initial Propulsive Force Between Sit to Walk and Sit to Stand in Healthy Subjects. Physiotherapy. 87(2). 87–87. 3 indexed citations
13.
Fedullo, Peter F., et al.. (2000). Chronic Thromboembolic Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine. 21(6). 549–560. 30 indexed citations
14.
Chapman, Andrea D., et al.. (1999). Right Heart Failure as the Dominant Clinical Picture in a Case of Primary Amyloidosis Affecting the Pulmonary Vasculature. Scottish Medical Journal. 44(4). 116–117. 8 indexed citations
15.
Dykhuizen, R S, et al.. (1997). Necrotizing sarcoid granulomatosis with extrapulmonary involvement. European Respiratory Journal. 10(1). 245–247. 30 indexed citations
16.
Kennedy, M., D Lamb, George King, & K.M. Kerr. (1997). Cell proliferation, cell loss and expression of bcl-2 and p53 in human pulmonary neoplasms. British Journal of Cancer. 75(4). 545–547. 12 indexed citations
17.
Kerr, K.M., et al.. (1997). Analysis of the sit-stand-sit movement cycle in normal subjects. Clinical Biomechanics. 12(4). 236–245. 160 indexed citations
18.
Kerr, K.M., et al.. (1995). Large Vessel Pulmonary Arteritis Mimicking Chronic Thromboembolic Disease. American Journal of Respiratory and Critical Care Medicine. 152(1). 367–373. 61 indexed citations
19.
Kerr, K.M., et al.. (1994). Analysis of the sit-stand-sit movement cycle: development of a measurement system. Gait & Posture. 2(3). 173–181. 17 indexed citations
20.
Kerr, K.M., et al.. (1988). A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma. British Journal of Cancer. 58(4). 419–422. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026